Dizal (Jiangsu) Pharmaceutical (SHA:688192) plans to present its latest research results of two lung cancer drugs at the 2025 World Conference on Lung Cancer in Spain, according to a Shanghai bourse filing on Thursday.
The Chinese pharmaceutical company will present study updates on Sunvozertinib and Golidocitinib.
Sunvozertinib was placed in priority review for marketing approval in the US.
The company's shares soared less than 6% during morning trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments